Blue Matter Launches Behavioral Science Center of Excellence to Decode and Predict Health Care Decisions in a Rapidly Evolving Biopharma Landscape

Blue Matter today announced the launch of its Behavioral Science Center of Excellence (BeSci CoE), a specialized capability within the Blue Matter Insights primary market research team. The CoE applies behavioral science as a strategic lens to decode the “why” behind the decisions made by healthcare professionals, patients, care partners, and other stakeholders.

Biopharma decisions hinge on knowing why customers do what they do. Traditional research does a good job of capturing what stakeholders say but often misses the unconscious drivers, biases, emotions, and contexts that shape behavior. The result is an incomplete picture in the moments where clarity matters most, including when developing positioning strategies, planning product launches, and making major lifecycle decisions.

"You don't need a survey to tell you that physicians see efficacy as the most important treatment decision driver," said Andrew Pilecki, Ph.D., Senior Market Research Director at Blue Matter. "What our clients come to us for is an understanding of why real-world prescribing often diverges from this perspective. That's where behavioral science comes in: it gives us the best way to bridge this 'say-do' gap."

The CoE serves a wide range of medical, market access, new product planning, and commercial functions in the industry’s largest companies as well as emerging innovators. Its work includes:

• Applying behavioral science frameworks in qualitative, quantitative, and mixed-method research to uncover the real drivers behind provider and patient decisions
• Translating behavioral insights into strategic and tactical recommendations
  Identifying early signals of how behavior and market dynamics will evolve

Behavioral science already informs many of Blue Matter’s existing methodologies; the CoE formalizes that expertise and embeds it across the firm’s integrated capabilities in primary market research and data analytics. Team members draw on robust academic credentials and years of applied biopharma experience. The CoE has and will continue to share its evidence-based discoveries through peer-reviewed manuscripts, white papers, conference presentations, and speaker events.

According to D’Arcy King, Ph.D., Partner and Head of Primary Market Research at Blue Matter, “Behavioral science isn’t a bolt-on technique for us. It is central to how we understand decision-making in complex, fast-moving markets.” She added, “By formalizing this expertise in a Center of Excellence, we are setting a higher bar for what behavioral-science-driven insights should deliver: clarity and confidence in stakeholder decision-making.”

About Blue Matter

Blue Matter (www.bluematterconsulting.com) is a global commercialization partner serving the life sciences industry. From its offices in North America, Europe and Asia, Blue Matter serves a broad spectrum of biopharmaceutical organizations, from top-20 global companies to emerging biotech firms. Blue Matter helps clients maximize value at the product, portfolio, and organization levels by providing market insights, strategic and operational consulting, and communications services.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260930768453/en/